Ampio spins off sexual dysfunction business Vyrix Pharmaceuticals

Ampio Pharmaceuticals (AMPE +3.3%) spins off its sexual dysfunction business into a standalone company called Vyrix Pharmaceuticals. The new entity will be funded through an IPO.

Vyrix's assets will include Zertane and Zertane-ED, late stage drugs for which the new entity will initiate further trials and develop commercialization and marketing partnerships.

The spin-off will be headed by Jarrett Disbrow, who was previously founder and CEO of Arbor Pharmaceuticals.

Ampio expects the IPO to take up to 12 months and that the company will maintain a 50%-80% ownership in Vyrix.

From other sites
Comments (1)
  • skleiniv
    , contributor
    Comments (88) | Send Message
    So how does this spin off affect current shareholders of AMPE stock? One of the reason's I invested in ampio to begin with was due to this drug in their pipeline. If their spining it off into a separate company and only maintain 50-80% ownership don't we all lose out on the full benefit and only take part in 50-20% ownership of the ED drug? If so, that sucks!
    13 Dec 2013, 01:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs